How Lynparza (olaparib) works in the body
Lynparza is a cancer drug that blocks a DNA-repair pathway called PARP signaling. PARP (poly(ADP-ribose) polymerase) enzymes help cells repair DNA single-strand breaks. When Lynparza inhibits PARP, DNA damage accumulates, and cancer cells that rely heavily on that repair route can die. This effect is especially strong in tumors with defects in homologous recombination repair, such as BRCA1 or BRCA2 mutations, because they have less ability to fix the more severe DNA damage that results when PARP is blocked [1].
What happens after PARP is blocked
By inhibiting PARP activity, Lynparza reduces the repair of DNA strand breaks. With unrepaired DNA lesions building up, cells can enter cell-cycle arrest and/or die through mechanisms linked to genomic instability [1].
Why it works better for some cancers (BRCA and similar defects)
Tumors with BRCA1/BRCA2 mutations—and some other homologous recombination repair deficiencies—tend to depend more on PARP-mediated repair. That creates a vulnerability that Lynparza targets. This concept is often described as synthetic lethality: the cancer cell can survive with either PARP inhibition or homologous recombination defects alone, but not when both problems are present at once [1].
What Lynparza is used for (context for how its mechanism is used)
Lynparza is used in certain cancers where PARP inhibition is expected to have a stronger effect, including specific breast and ovarian cancers and metastatic castration-resistant prostate cancer with relevant genetic or clinical features that suggest sensitivity to PARP blockade [1].
Does Lynparza work only in BRCA-mutated tumors?
The strongest and most direct rationale is PARP inhibition in tumors with homologous recombination repair defects (like BRCA mutations). Some clinical uses also focus on biomarkers that suggest broader DNA repair impairment, but the precise eligibility depends on the specific indication and testing used for that cancer type [1].
What are the key limitations or safety implications tied to the mechanism?
Because Lynparza interferes with DNA repair, its main toxicities often reflect effects on rapidly dividing tissues and blood cell production. In practice, clinicians monitor blood counts and adjust dosing if needed. This links back to how blocking DNA repair can harm both cancer cells and normal cells that depend on similar repair processes [1].
Sources
- Lynparza (olaparib) | FDA Prescribing Information